Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice
Rajamäki, Aino (University of Eastern Finland)
Sorigue, Marc (Trialing Health (Barcelona))
Prusila, Roosa E.I. (Kuopio University Hospital (Finlàndia))
Kuusisto, Milla E.L. (LänsiPohja Central Hospital)
Kuitunen, Hanne (Oulu University Hospital (Finlàndia))
Jantunen, Esa (Kuopio University Hospital ( Finlàndia))
Mercadal, Santiago (Hospital Duran i Reynals (Barcelona))
Turpeenniemi-Hujanen, Taina (University of Oulu (Finlàndia))
Sancho, Juan Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Sunela, Kaisa (Finnish Medicines Agency FIMEA (Barcelona))
Kuittinen, Outi (Kuopio University Hospital (Finlàndia))

Date:	2024
Abstract:	Background: The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies. Patients and methods: We set out to determine progression-free survival (PFS) after front line, second line, and third line of therapy on the basis of relevant biological characteristics and therapeutic choices. Patients (n = 743, 51% females, median 60 years old) diagnosed with grade 1-2 FL between 1997 and 2016 in nine institutions were included. Results: The median PFS1, PFS2, and PFS3 were 8. 1 years (95% confidence interval [CI]: 7-9. 3 years), 4. 2 years (95% CI: 2. 8-5. 6 years) and 2. 2 years (95% CI 1. 7-2. 8 years). We found longer PFS1 for (1) females, (2) younger age, (3) lower-risk follicular lymphoma international prognostic index (FLIPI), (4) standard intensity (over low intensity) regimens and (5) immunochemotherapy strategies and (6) maintenance rituximab. We found a shorter PFS2 for patients who received front-line immunochemotherapy. Older age at diagnosis correlated with a shorter PFS3. Intensity of front-line chemotherapy, maintenance, or POD24 status did not correlate with PFS2 or PFS3 in this dataset. Interpretation: With current immunochemotherapy strategies, the natural course of FL is characterized by shorter-lasting remissions after each relapse. It will be interesting to see whether new therapies can alter this pattern.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Follicular lymphoma ; Survival ; Progression-free ; Treatment
Published in:	Acta Oncologica, Vol. 63 (2024) , p. 267-272, ISSN 1651-226X

DOI: 10.2340/1651-226X.2024.24377
PMID: 38709114

6 p, 484.6 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles